Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 2, 2015, Pages 172-178

  Sinanovic, E ^a   Ramma, L ^a   Vassall, A ^b   Azevedo, V ^c   Wilkinson, L ^d   Ndjeka, N ^e   McCarthy, K ^f   Churchyard, G ^f   Cox, H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Red Cross War Memorial Children's Hospital   (United Kingdom)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^f AURUM INSTITUTE   (South Africa)

Author keywords

Budget impact; Costing; Decentralization; MDR TB; Rifampicin resistant tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CLOFAZIMINE; ETHIONAMIDE; KANAMYCIN; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TERIZIDONE; TUBERCULOSTATIC AGENT;

ARTICLE; BUDGET; CLINICAL EXAMINATION; CONSULTATION; COST CONTROL; DECENTRALIZATION; DRUG COST; HEALTH CARE COST; HEALTH CARE DELIVERY; HOSPITAL CARE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; MICROSCOPY; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT CARE; PRIORITY JOURNAL; SOUTH AFRICA; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULOSIS RAPID TEST; ECONOMIC MODEL; ECONOMICS; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MODELS, ECONOMIC; RIFAMPIN; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84937120087     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0421     Document Type: Article

References (15)

1. World Health Organization. Global tuberculosis report, 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
2. Pooran A, Pieterson E, Davids M, Theorn G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLOS ONE 2013; 8: e54587.
3. National Health Laboratory Service. GeneXpert MTB/RIF Implementation Progress Report October 2013. Pretoria, South Africa. NHLS, 2013. http://www.nhls.ac.za/?page=genexpert-implementation-progress-reports&id=75. Accessed October 2014.
4. World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
5. South African National Department of Health. Management of drug-resistant tuberculosis: policy guidelines. Pretoria, South Africa: DoH, 2011.
6. Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpertw MTB/RIF in South Africa. PLOS ONE 2012; 7: 36966.
7. Schnippel K, Rosen S, Shearer K, et al. Costs of inpatient treatment for multi-drug resistant tuberculosis in South Africa. Trop Med Int Health 2013; 18: 109-116.
8. Cox H, Hughes J, Daniels J, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis 2014; 18: 441-448.
9. Médecins Sans Frontières. Scaling up diagnosis and treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Research Report. Cape Town: MSF, 2011. http://www.msf.org.za/msf-publications/scaling-diagnosis-and-treatment-drugresistant-tuberculosis-khayelitsha-south. Accessed October 2014.
10. Statistics South Africa. Statistical Release P0141 Consumer Price Index February 2012. Pretoria, South Africa: Statistics South Africa, 2012. http://www.statssa.gov.za/publications/P0141/P0141February2012.pdf. Accessed October 2014.
11. Statistics South Africa. Statistical Release P0141 Consumer Price Index February 2013. Pretoria, South Africa: Statistics South Africa, 2013. http://www.statssa.gov.za/publications/P0141/P0141February2013.pdf. Accessed October 2014.
12. Brust J C, Shah N S, Scott M, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 2012; 16: 998-1004.
13. Padayatchi N, Friedland G. Decentralised management of drugresistant tuberculosis (MDR- and XDR-TB) in South Africa: an alternative model of care. Int J Tuberc Lung Dis 2008; 12: 978-980.
14. Ndjeka N. Drug-resistant tuberculosis in South Africa. Pretoria, South Africa: National Department of Health, 2013.
15. Menzies N A, Cohen T, Lin H-H, Murray M, Salomon J A. Population health impact and cost effectiveness of tuberculosis diagnosis with Xpertw MTB/RIF: a dynamic simulation and economic evaluation. PLOS MED 2012; 9: e1001347.